UC Berkeley's DNA-editing technology spinout has raised $10m from RA Capital in addition to the $65m it pocketed in November.
Metagenomi, a US-based gene editing technology spinout of University of California, Berkeley, received $10m in additional series A financing from RA Capital Management to bring the round to $75m.
RA Capital is co-leading the round with chemical and pharmaceutical producer Bayer subsidiary Leaps by Bayer and venture capital fund Humboldt Fund.
The first tranche in November 2020 also featured Sozo Ventures, Agent Capital, InCube Ventures and HOF Capital.
Founded in 2018, Metagenomi is working on DNA…
